Abstract: The present disclosure pertains to the use of Imatinib or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension. A patient status relative to their baseline status of at least one of a proteomic biomarker, a protein biomarker, a transcriptomic biomarker, a patient specific genetic signature, an RNA expression biomarker signature, or a timed walk distance may be used in adjusting at least one of a dosage of imatinib or a treatment duration.

Abstract: This disclosure concerns improved capabilities for evaluating whether additional medical tests need to be conducted for a diagnosis of a pulmonary arterial hypertension (PAH) condition in a patient. The method includes determining that the patient is at rest and measuring a partial pressure of carbon dioxide in a composite gas, comprising: transferring an expiration from the patient's mouth to a carbon dioxide analyzer; measuring end tidal carbon dioxide (EtCO2) from each of a plurality of oral expirations from the patient; and calculating a composite EtCO2 value. The method further includes comparing the composite EtCO2 value to a range of stored carbon dioxide partial pressure values; generating a signal indicating whether additional medical tests need to be conducted in response to the comparing; and providing the generated signal to an indicator, the indicator adapted to respond to the generated signal to provide an output in a human cognizable format.

Abstract: This disclosure concerns improved capabilities for evaluating whether additional medical tests need to be conducted for a diagnosis of a pulmonary arterial hypertension (PAH) condition in a patient. The method includes determining that the patient is at rest and measuring a partial pressure of carbon dioxide in a composite gas, comprising: transferring an expiration from the patient's mouth to a carbon dioxide analyzer; measuring end tidal carbon dioxide (EtCO2) from each of a plurality of oral expirations from the patient; and calculating a composite EtCO2 value. The method further includes comparing the composite EtCO2 value to a range of stored carbon dioxide partial pressure values; generating a signal indicating whether additional medical tests need to be conducted in response to the comparing; and providing the generated signal to an indicator, the indicator adapted to respond to the generated signal to provide an output in a human cognizable format.

Abstract: This disclosure concerns improved capabilities for evaluating pulmonary arterial hypertension (PAH). A system and method of evaluating PAH in a subject may include measuring end tidal partial pressure of exhaled carbon dioxide in the subject, wherein the measurement is made orally using described systems or devices. Integrated sensors enable the measurement and characterization of other respiratory gas components, some of which may be indicative of disease. The system and method can be used to monitor a course of treatment for PAH.

Abstract: This disclosure concerns improved capabilities for evaluating pulmonary arterial hypertension (PAH). A system and method of evaluating PAH in a subject may include measuring end tidal partial pressure of exhaled carbon dioxide in the subject, wherein the measurement is made orally using described systems or devices. Integrated sensors enable the measurement and characterization of other respiratory gas components, some of which may be indicative of disease. The system and method can be used to monitor a course of treatment for PAH.

Abstract: This disclosure concerns improved capabilities for evaluating pulmonary arterial hypertension (PAH). A system and method of evaluating PAH in a subject may include measuring end tidal partial pressure of exhaled carbon dioxide in the subject, wherein the measurement is made orally using described systems or devices. Integrated sensors enable the measurement and characterization of other respiratory gas components, some of which may be indicative of disease. The system and method can be used to monitor a course of treatment for PAH.

Abstract: In embodiments of the present invention improved capabilities are described for evaluating pulmonary embolism. A system and method of evaluating pulmonary embolism in a subject may include measuring end tidal partial pressure of exhaled carbon dioxide in the subject, wherein the measurement is made orally, obtaining a clinical approximation of dead space ventilation based on the measurement, and excluding pulmonary embolism when the end tidal partial pressure of exhaled carbon dioxide reaches a threshold.